The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation

Bone Marrow Transplantation
B E ShawJ A Madrigal

Abstract

The importance of matching for HLA-DPB1 in unrelated donor haematopoietic stem cell (HSC) transplantation is little understood. Most transplant centres do not, currently, prospectively match for DPB1, but emerging data show that DPB1 matching does play a role in determining outcome. We studied the impact of HLA-DPB1 matching on outcome in 143 recipients of T-cell depletion transplants, who matched with their respective unrelated donors (allelic level) at HLA-A, -B, -C, -DRB1 and -DQB1. Of those matched at DPB1, 47.2% (17/36) developed acute graft-versus-host disease (aGvHD) as compared to 66.3% (55/83) of those who were mismatched. This led to a 19.1% (95% CI 0.1-38.3%) increase in the chance of developing aGvHD in mismatched patients (P=0.049). Relapse of the original disease occurred in 51 recipients; 23 of 37 (62%) matched at both DPB1 alleles, 28 of 82 (34%) were mismatched at one or two DPB1 alleles. Thus, there was a significantly higher relapse rate (P=0.0011) in transplant recipients who matched at both DPB1 alleles. In conclusion, a donor/recipient DPB1 match was associated with a significantly lower incidence of aGvHD and a significantly higher incidence of disease relapse. This study provides further evidence for an ...Continue Reading

References

Oct 17, 1992·Lancet·S TonksJ G Bodmer
Mar 1, 1991·Tissue Antigens·J G BodmerT Sasazuki
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A B BegovichH A Erlich
Oct 8, 1993·Science·L RicheldiC Saltini
Jan 1, 1993·Human Immunology·U B Gyllensten, H A Erlich
Apr 12, 2001·British Journal of Haematology·E W PetersdorfJ A Hansen
Oct 9, 2002·Tissue Antigens·Steven E Marsh, UNKNOWN WHO Nomenclature Committee for Factors of the HLA System
Dec 21, 2002·Tissue Antigens·S G E MarshP I Terasaki

❮ Previous
Next ❯

Citations

Apr 23, 2005·Seminars in Hematology·Effie W Petersdorf, Mari Malkki
Nov 19, 2004·Current Opinion in Hematology·Effie W Petersdorf
Jul 2, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kirsten A ThusEric Spierings
Jun 12, 2008·British Journal of Haematology·Katarina LudajicHildegard T Greinix
Apr 21, 2007·Tissue Antigens·B E ShawE W Petersdorf
Feb 24, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yasuo MorishimaUNKNOWN Japan Marrow Donor Program
Jan 18, 2006·Seminars in Hematology·Effie W Petersdorf, Mari Malkki
Aug 9, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Caroline E RuttenJ H Frederik Falkenburg
Jul 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Pascale LoiseauColette Raffoux
Jul 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mari MalkkiUNKNOWN International Histocompatibility Working Group in Transplantation
Aug 19, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Elisabetta ZinoKatharina Fleischhauer
Jun 28, 2017·Leukemia·T YabeUNKNOWN Japanese Cord Blood Transplantation Histocompatibility Research Group
Feb 9, 2010·Genetic Testing and Molecular Biomarkers·Dina ShammaaRami A R Mahfouz
Jun 15, 2004·Bone Marrow Transplantation·J-M TiercyUNKNOWN Chronic Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT)
Mar 10, 2018·Frontiers in Immunology·Esteban Arrieta-BolañosKatharina Fleischhauer
Feb 25, 2021·HLA : Immune Response Genetics·Francisco BoixKaty Latham
Aug 5, 2021·Leukemia Research Reports·Mireille HunzikerMichael Medinger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.